China has operationalised its new biosecurity law to fortify the legal cover for the establishment and safe operation of more bio labs in the country amidst questions whether the COVID-19 originated from such a laboratory in Wuhan.
The novel coronavirus emerged at China's central Wuhan city in December 2019 and became a pandemic, upending life across the globe.
Under the new Biosecurity Law, China will continue to build and approve more labs specialising in advanced pathogenic microbiology with a scrupulous and scientific manner, the country's Deputy Minister of Science and Technology Xiang Libin said.
China will carry out major scientific research to enhance its biosecurity science and technological capacity against future infectious diseases, state-run Global Times quoted Xiang as saying.
The ministry has examined and approved the construction of three biosafety level-4 labs, or P4 labs, and 88 biosafety level-3 labs, or P3 labs, in China, he said.
A biosafety level (BSL), or pathogen/protection level, is a set of biocontainment precautions required to isolate dangerous biological agents in an enclosed laboratory facility.
The levels of containment range from the lowest biosafety level 1 (BSL-1) to the highest at level 4 (BSL-4).
Bai Chunli, president of the Chinese Academy of Sciences, said in April last year that China had two P4 labs besides 81 P3 labs in operation or approved for construction.
In contrast, the US has 12 P4 and 1,500 P3 labs, the Global Times report said.
Bio labs acquired significance as the US has alleged that the COVID-19 may have emanated from the Wuhan Institute of Virology (WIV) which is a P-4 bio lab. China has strongly denied the charge.
A team of WHO experts, which probed the origin of the coronavirus, concluded last month that all hypotheses included the allegation that COVID-19 could have emanated from a bio lab "remained open".
World Health Organisation (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, while receiving the report of the international experts' team which visited Wuhan, said on March 30 that as far as the WHO is concerned, all hypotheses remain on the table.
This report is a very important beginning, but it is not the end. We have not yet found the source of the virus, and we must continue to follow the science and leave no stone unturned as we do, he said.
Significantly, Tedros said the team has concluded that leak from the WIV as alleged by former US president Donald Trump is the least likely hypothesis but it requires further probe.
The team also visited several laboratories in Wuhan and considered the possibility that the virus entered the human population as a result of a laboratory incident.
However, I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions, Tedros said.
Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy, the WHO chief added.
Yang Zhanqiu, deputy director of the pathogen biology department at Wuhan University, told the Global Times on Thursday that the law on biosafety is a timely move for China to detail the construction and management of biosafety labs and provide a legal shield for scientific projects on biosafety, including infectious diseases, to be carried out in a scrupulous and professional manner.
According to John Hopkins coronavirus tracker, China has so far reported 102,152 cases and 4,845 deaths. Globally the contagion has infected 139,228,122 people and killed 29,89,103, it said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)